DNA Jan 2025 3.500 call
| Previous Close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 3.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.1000 - 0.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2.69k |
PR NewswireGinkgo Bioworks Reports First Quarter 2024 Financial Results
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2024. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.
PR NewswireGreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener
GreenLab, an emerging next generation plant-biotechnology company producing complex proteins in corn, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Together, GreenLab and Ginkgo aim to enable production of brazzein, a sweet-tasting protein found in the fruit of the native West African Oubli plant, at commercial scale. The two companies have previously partnered on a project to develop an enzyme for
PR NewswireGinkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics. These presentations demonstrate the power of Ginkgo's platform to drive innovation in the discovery and development of genetic medicines.
